Alexion Pharmaceuticals Inc. shares fell in the extended session Monday after the biotech company said its treatment for a rare neuromuscular disease did not reach its main goal of a late-stage clinical trial. Following a brief halt, Alexion shares dropped 8.9% to $141.28. The company said a Phase III study of its drug Soliris did not significantly improve symptoms of people with refractory generalized myasthenia gravis, a condition characterized by profound muscle weakness that can result in slurred speech, choking and respiratory failure.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News